ACRYSOF® Toric NATURAL T9 Intraocular Lens (IOL)
ACRYSOF® Toric NATURAL T9 Intraocular Lens (IOL)
The purpose of this study is to describe rates of spatial distortions related to intraocular
 lens (IOL) misalignment for ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 when
 implanted bilaterally into the capsular bag following phacoemulsification in adult patients
 with bilateral cataract and regular corneal astigmatism. Subjects were implanted with the
 Model SN60T9 in the first operative (study) eye and either Model SN60T9 or Model SN60T8 in
 the second operative eye.
Inclusion Criteria:

 -  Adults, 21 years of age or older at the time of surgery, of either gender or any race,
 diagnosed with bilateral cataracts;

 -  Calculated lens power is within the available range;

 -  Willing and able to complete all required postoperative visits;

 -  Planned cataract removal by phacoemulsification;

 -  Potential postoperative visual acuity of 0.2 logMAR or better in study eyes;

 -  Preoperative astigmatism of 4.11 - 4.62 Diopter (D) of predicted crossed cylinder as
 calculated by the study specific web-based Alcon® Toric IOL Calculator in the first
 operative eye. Corneal incisions made to reduce astigmatism will not be allowed during
 the course of the study;

 -  Preoperative astigmatism of 3.60 - 4.62 D of predicted crossed cylinder as calculated
 by study specific web-based Alcon® Toric IOL Calculator in the second operative eye;

 -  Clear intraocular media other than cataract;

 -  Able to comprehend and sign a statement of informed consent;

 -  Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR;

 -  Pupil size greater than or equal to 6 mm after dilation;

 -  The subject must be able to undergo second eye surgery within 30 days of first eye
 surgery.

 Exclusion Criteria:

 -  Irregular corneal astigmatism;

 -  Keratopathy/Keratectasia - any corneal abnormality, other than regular corneal
 astigmatism, including but not limited to the following; keratoconus, keratoglobus,
 keratolysis, keratomalacia, keratomycosis, and corneal plana;

 -  Any inflammation or edema (swelling) of the cornea, including but not limited to the
 following; keratitis, keratoconjunctivitis, and keratouveitis;

 -  Previous corneal refractive surgery;

 -  Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or
 other retinal disorders) that are predicted to cause future acuity losses to a level
 worse than 0.2 logMAR;

 -  Amblyopia;

 -  Clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial
 dystrophy);

 -  Diabetic retinopathy;

 -  Extremely shallow anterior chamber, not due to swollen cataract;

 -  Microphthalmos;

 -  Previous retinal detachment;

 -  Previous corneal transplant;

 -  Recurrent severe anterior or posterior segment inflammation of unknown etiology;

 -  Rubella or traumatic cataract;

 -  Iris neovascularization;

 -  Uncontrolled glaucoma;

 -  Aniridia;

 -  Optic nerve atrophy;

 -  Pregnancy;

 -  Any subject currently participating in another investigational drug or device study
 that may confound the results of this investigation.